News & Updates
Filter by Specialty:

Psoriasis control maintained with less frequent guselkumab dosing
11 Aug 2024
byJairia Dela Cruz
A 16-week dosing interval for the IL-23 inhibitor guselkumab appears to sufficiently keep psoriasis controlled among patients who have achieved complete skin clearance shortly after starting standard treatment with the drug, according to the phase IIIb GUIDE clinical trial.
Psoriasis control maintained with less frequent guselkumab dosing
11 Aug 2024
Cabozantinib offers survival benefits to ICI-treated HCC patients
11 Aug 2024
A phase II trial of cabozantinib demonstrates the study drug’s efficacy in patients with hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitor (ICI) regimens.
Cabozantinib offers survival benefits to ICI-treated HCC patients
11 Aug 2024
Score model predicts prognosis in older adults with pneumonia
10 Aug 2024
A new prediction score model identifies older patients with community-onset pneumonia who are nearing the end of life and need advance care planning (ACP) practices, reports a study.